X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN LTD CADILA HEALTHCARE/
LUPIN LTD
 
P/E (TTM) x 31.7 19.8 160.4% View Chart
P/BV x 5.9 2.7 220.0% View Chart
Dividend Yield % 0.8 0.9 85.3%  

Financials

 CADILA HEALTHCARE   LUPIN LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
LUPIN LTD
Mar-17
CADILA HEALTHCARE/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4601,750 26.3%   
Low Rs3051,384 22.0%   
Sales per share (Unadj.) Rs92.1387.4 23.8%  
Earnings per share (Unadj.) Rs14.856.6 26.2%  
Cash flow per share (Unadj.) Rs18.576.8 24.1%  
Dividends per share (Unadj.) Rs3.207.50 42.7%  
Dividend yield (eoy) %0.80.5 174.8%  
Book value per share (Unadj.) Rs68.0298.9 22.7%  
Shares outstanding (eoy) m1,023.74451.58 226.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.24.0 102.7%   
Avg P/E ratio x25.827.7 93.3%  
P/CF ratio (eoy) x20.720.4 101.5%  
Price / Book Value ratio x5.65.2 107.3%  
Dividend payout %21.613.2 163.1%   
Avg Mkt Cap Rs m391,581707,513 55.3%   
No. of employees `00016.916.8 100.4%   
Total wages/salary Rs m15,00228,495 52.6%   
Avg. sales/employee Rs Th5,594.510,418.3 53.7%   
Avg. wages/employee Rs Th890.11,697.0 52.5%   
Avg. net profit/employee Rs Th899.91,523.0 59.1%   
INCOME DATA
Net Sales Rs m94,295174,943 53.9%  
Other income Rs m1,2861,065 120.7%   
Total revenues Rs m95,581176,008 54.3%   
Gross profit Rs m19,03644,931 42.4%  
Depreciation Rs m3,7509,122 41.1%   
Interest Rs m4501,525 29.5%   
Profit before tax Rs m16,12235,349 45.6%   
Minority Interest Rs m338-72 -471.4%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2899,785 13.2%   
Profit after tax Rs m15,16825,575 59.3%  
Gross profit margin %20.225.7 78.6%  
Effective tax rate %8.027.7 28.9%   
Net profit margin %16.114.6 110.0%  
BALANCE SHEET DATA
Current assets Rs m60,223119,542 50.4%   
Current liabilities Rs m53,05861,206 86.7%   
Net working cap to sales %7.633.3 22.8%  
Current ratio x1.12.0 58.1%  
Inventory Days Days7076 91.9%  
Debtors Days Days8890 98.1%  
Net fixed assets Rs m72,984131,660 55.4%   
Share capital Rs m1,024903 113.4%   
"Free" reserves Rs m68,576134,073 51.1%   
Net worth Rs m69,600134,976 51.6%   
Long term debt Rs m24,68456,478 43.7%   
Total assets Rs m152,207266,073 57.2%  
Interest coverage x36.824.2 152.3%   
Debt to equity ratio x0.40.4 84.8%  
Sales to assets ratio x0.60.7 94.2%   
Return on assets %10.310.2 100.7%  
Return on equity %21.818.9 115.0%  
Return on capital %17.919.3 93.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28081,885 26.0%   
Fx outflow Rs m10,87421,506 50.6%   
Net fx Rs m10,40660,378 17.2%   
CASH FLOW
From Operations Rs m13,49541,148 32.8%  
From Investments Rs m-29,103-25,287 115.1%  
From Financial Activity Rs m23,1584,332 534.6%  
Net Cashflow Rs m7,55620,193 37.4%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  VENUS REMEDIES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - STERLING BIOTECH COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS